finance.yahoo.comOct 9

Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact

Alumis presented Phase III trial results showing its psoriasis drug, envudeucitinib, achieved significant efficacy and safety milestones. The company plans to submit an NDA in Q4 2026, aiming to compete with Bristol Myers Squibb's Sotyktu, which had $291m in 2023 sales.

Original reporting

finance.yahoo.com

Published Oct 9, 2026, 5:11 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 9, 2026, 5:15 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

Med

Why it matters

Positive efficacy and safety data could drive investor optimism ahead of an NDA filing later this year.

Market read

First report of pivotal trial data; may affect biotech sector sentiment and competitor valuations.

What to watch

Competitive landscape with BMS's Sotyktu and upcoming FDA review timelines.

Relevance 9/10Novelty 9/10Timing: upon data release

Background

Alumis, a California‑based biopharma, released Phase III trial results for its TYK2 inhibitor envudeucitinib in psoriasis.

Market effects

Sector

Phase III psoriasis data may boost the broader TYK2 inhibitor and oral psoriasis market.

Regional

Limited to U.S. biotech investors; no immediate regional effect.

Global

Potential interest from global dermatology drug developers.

Counterpoint

What could challenge this read

If the data fails to translate into regulatory approval, the hype could fade quickly.

Key entities

company
Alumis
Biopharma developing envudeucitinib for psoriasis.
company
Bristol Myers Squibb
Competitor with Sotyktu, a TYK2 inhibitor.

Read at source ← All news

Med

Wells Fargo maintains Alumis at Overweight, lowers price target to $18 from $25

Wells Fargo downgraded its price target for Alumis to $18 from $25, a 28% decrease, while maintaining an Overweight rating. The new target implies a 193.6% upside from the Nov 12 close of $6.13, according to the bank.

tradingview.comNov 13

$ALMSMedAI 8/10

Alumis 3Q 2026: Revenue $1.91M, EPS ($0.73) — 10-Q Summary

Alumis reported 3Q 2026 revenue of $1.91M, down 8% YoY, with a net loss of $94.88M, improved 14% YoY. R&D expenses fell 17% due to completed trials. The company plans an NDA submission for envu in psoriasis by year-end and is exploring strategic alternatives for lonigutamab.

tradingview.comNov 12

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

tradingview.comNov 12

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

SEC EDGAR 8-KNov 12

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.

finance.yahoo.comNov 12

$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

mugglehead.comOct 9